Preview

Rational Pharmacotherapy in Cardiology

Advanced search

APPROACHES TO PERSONALIZED THERAPY

https://doi.org/10.20996/1819-6446-2018-14-3-418-424

Full Text:

Abstract

Approaches to personalized therapy based on practical work of physicians are discussed. Personalized treatment considers patient’s interests and position, mechanisms of symptoms, somatic and mental comorbidities, chrono medicine, environment, genetics, and prognosis. Personalized treatment may be more effective, safe and inexpensive in compare with of traditional standardized care based on randomized controlled trials and clinical practice guidelines. Limitations and weaknesses of medical guidelines of authoritative professional societies are also discussed. Recommendations of clinical guidelines are based on randomized controlled trials with strict selection of patients without severe comorbid diseases. Accordingly, trials and guidelines conclusions cannot be applied for patients with heavy comorbidity. This justifies the need for organizational solutions and computer programs for support personalized treatment of patients. It is important to develop institute of primary care physicians and to train specialists in field of comorbid somatic diseases and mental disorders.

About the Author

F. I. Belyalov
Irkutsk State Medical Academy of Postgraduate Education
Russian Federation

MD, PhD, Professor, Chair of Gerontology and Geriatrics, 

Yubileinii mkrn 100, Irkutsk, 664079



References

1. Belialov F. Has personalized medicine the future? Klinicheskaya Meditsina. 2014;73-4. (In Russ.) [Белялов Ф.И. Есть ли будущее у персонифицированной медицины? Клиническая Медицина. 2014;6:73-4].

2. Lundh A., Lexchin J., Mintzes B., et al. Industry sponsorship and research out-come. Cochrane Database Syst Rev. 2017;2:MR000033. doi:10.1002/14651858.MR000033.pub3.

3. Belyalov F.I. Drugs efficiency and safety: the role of pharmaceutical industry. Rational Pharmacotherapy in Cardiology. 2015;11(4):420-5. (In Russ.) [Белялов Ф.И. Эффективность и безопасность лекарств: роль фармацевтической индустрии. Рациональная Фармакотерапия в Кардиологии. 2015;11(4):420-5]. doi:10.20996/1819-6446-2015-11-4-420-425.

4. McMurray J.J.V., Packer M., Desai A.S., et al. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. New England Journal of Medicine. 2014;371:993-1004. doi:10.1056/NEJMoa1409077.

5. Tibrewala A., Jivan A., Oetgen W.J., Stone N.J. A Comparative Analysis of Current Lipid Treatment Guidelines. J Am Coll Card. 2018;71(7):794. doi:10.1016/j.jacc.2017.12.025

6. Institute of Medicine. Clinical Practice Guidelines We Can Trust. Washington, DC: National Academies Press; 2011. [cited 2018 Jan 25]. Available from: https://www.ncbi.nlm.nih.gov/books/ NBK209539/.

7. Sox H.C. Conflict of Interest in Practice Guidelines Panels. JAMA. 2017;317(17):1739-40. doi: 10.1001/jama.2017.2701.

8. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2013;34(39):3035-87. doi:10.1093/eurheartj/eht108.

9. Oganov R.G., Denisov I.N., Simanenkov V.I., et al. Comorbidities in practice. Clinical guidelines. Cardiovascular Therapy and Prevention. 2017;16(6):5-56. (In Russ.) [Оганов Р.Г., Денисов И.Н., Симаненков В.И. и соавт. Коморбидная патология в клинической практике. Клинические рекомендации. Кардиоваскулярная Терапия и Профилактика. 2017;16(6):5-56]. doi:10.15829/1728-8800-2017-6-5-56.

10. Washam J.B., Herzog C.A., Beitelshees A.L., et al. Pharmacotherapy in Chronic Kidney Disease Patients Presenting With Acute Coronary Syndrome: A Scientific Statement From the American Heart Association. Circulation. 2015;131(12):1123-49. doi:10.1161/CIR.0000000000000183.

11. Schmidt M., Lamberts M., Olsen A.M., et al. Cardiovascular safety of non-aspirin non-steroidal antiinflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J. 2016;37(13):1015-23. doi:10.1093/eurheartj/ehv505.

12. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37(29):2315-81. doi:10.1093/eurheartj/ehw106.

13. Jørgensen M.E., Andersson C., Nørgaard B.L., et al. Functional Testing or Coronary Computed Tomography Angiography in Patients With Stable Coronary Artery Disease. J Am Coll Card. 2017;69(14):1761. doi:10.1016/j.jacc.2017.01.046.

14. Foy A.J., Dhruva S.S., Peterson B., et al. Coronary Computed Tomography Angiography vs Functional Stress Testing for Patients With Suspected Coronary Artery Disease. A Systematic Review and Metaanalysis. JAMA Intern Med. 2017;177(11):1623-31. doi:10.1001/jamainternmed.2017.4772.

15. Manzoli L., Flacco M.E., Boccia S., et al. Generic versus brand-name drugs used in cardiovascular diseases. Eur J Epidemiol. 2016;31(4):351-68. doi:10.1007/s10654-015-0104-8.

16. Cha M.J., Moon H.S., Sohn J.H., et al. Chronic Daily Headache and Medication Overuse Headache in First-Visit Headache Patients in Korea: A Multicenter Clinic-Based Study. J Clin Neurol. 2016;12(3):316-22. doi:10.3988/jcn.2016.12.3.316.

17. Merikangas K.R., Cui L., Richardson A.K., et al. Magnitude, impact, and stability of primary headache subtypes: 30 year prospective Swiss cohort study. BMJ 2011;343. doi:10.1136/bmj.d5076.

18. Lim A.Y., Park T.K., Cho S.W., et al. Clinical implications of low-dose aspirin on vasospastic angina patients without significant coronary artery steno-sis; a propensity score-matched analysis. International Journal of Cardiology. 2016;221:161-6. doi:10.1016/j.ijcard.2016.06.195.

19. Ishii M., Kaikita K., Sato K., et al. Impact of aspirin on the prognosis in patients with coronary spasm without significant atherosclerotic stenosis. International Journal of Cardiology. 2016;220:328-32. doi:10.1016/j.ijcard.2016.06.157.

20. Kim C.H., Park T.K., Cho S.W., et al. Impact of different nitrate therapies on longterm clinical outcomes of patients with vasospastic angina: A propensity score-matched analysis. Int J Card. 2018;252:1- 5. doi:10.1016/j.ijcard.2017.07.031.

21. Belyalov F. Treatment of diseases in comorbidity. 10th ed. Moscow: GEOTAR-media; 2016. (In Russ.) [Белялов Ф.И. Лечение болезней в условиях коморбидности. 10-е изд. Москва: ГЭОТАРМедиа; 2016].

22. Kumar S., de Lusignan S., McGovern A., et al. Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care. BMJ. 2018;360:k342. doi:10.1136/bmj.k342.

23. Bansal N., Szpiro A., Reynolds K., et al. Long-term outcomes associated with implantable cardioverter defibrillator in adults with chronic kidney disease. JAMA Intern Med. 2018;178(3):390-8. doi:10.1001/jamainternmed.2017.8462.

24. Belyalov F. Psychosomatics. 7th ed. Moscow: GEOTAR-media; 2018. (In Russ.) [Белялов Ф.И. Психосоматика. 7-е изд. Москва: ГЭОТАР-Медиа; 2018].

25. Becker A.E., Kleinman A. Mental Health and the Global Agenda. New Engl J Med. 2013;369(1):66- 73. doi:10.1056/NEJMra1110827.

26. Rao M.P., Vinereanu D., Wojdyla D.M., et al. Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. Am J Med. 2018;131(3):269-75.e262. doi:10.1016/j.amjmed.2017.10.036.

27. Zhao R., Chen S., Wang W., et al. The impact of short-term exposure to air pollutants on the onset of out-of-hospital cardiac arrest: A systematic review and meta-analysis. Int J Cardiol. 2017;226:110-7. doi:10.1016/j.ijcard.2016.10.053.

28. Huang C., Moran A.E., Coxson P.G., et al. Potential Cardiovascular and Total Mortality Benefits of Air Pollution Control in Urban China. Circulation. 2017;136(17):1575. doi:10.1161/CIRCULATIONAHA.116.026487.

29. Bañeras J., Ferreira-González I., Marsal J.R., et al. Short-term exposure to air pollutants increases the risk of ST elevation myocardial infarction and of infarct-related ventricular arrhythmias and mortality. Int J Card. 2018;250:35-42. doi:10.1016/j.ijcard.2017.10.004.

30. Onozuka D., Hagihara A. Extreme temperature and out-of-hospital cardiac arrest in Japan: A nationwide, retrospective, observational study. Sci Total Environ. 2017;575:258-64. doi:10.1016/j.scitotenv.2017.01.081.

31. Kontsevaya A.V., Balanova J.A., Loukianov M.M., Khudyakov M.B., Belova O.A., Romanchuk S.V. Excess winter cardiovascular morbidity in Ivanovo Region in 2009-2013 years. Rational Pharmacotherapy in Cardiology. 2015;11(5):450-8. (In Russ.) [Концевая А.В., Баланова Ю.А., Лукьянов М.М. и др. Избыточная заболеваемость сердечно-сосудистыми заболеваниями в зимнийпериод в Ивановскойобласти в 2009-2013 гг. Рациональная Фармакотерапия в Кардиологии. 2015;11(5):450-8]. doi:10.20996/1819-6446-2015-11-5-450-458.

32. Hensel M., Stuhr M., Geppert D., et al. Relationship between ambient temperature and frequency and severity of cardiovascular emergencies: A prospective observational study based on out-of-hospital care data. Int J Card. 2017;228:55. doi:10.1016/j.ijcard.2016.11.155.

33. Belyalov F.I., Samorodskaya I.V., Pogodaeva S.V. Comparative Analysis of All-cause and Cardiovascular Mortality in Moscow and Irkutsk. Rational Pharmacotherapy in Cardiology. 2016;12(4):366-75. (In Russ.) [Белялов Ф.И., Самородская И.В., Погодаева С.В. Сравнительный анализ общей и сердечно-сосудистой смертности населения в Москве и Иркутске. Рациональная Фармакотерапия в Кардиологии. 2016;12(4):366-75]. doi:10.20996/1819-6446-2016-12-4-366-375.

34. Rohatgi R.K., Sugrue A., Bos J.M., et al. Contemporary Outcomes in Patients with Long QT Syndrome. J Am Coll Card. 2017;70(4):453. doi:10.1016/j.jacc.2017.05.046.

35. Personalized Medicine Coalition. The Personalized Medicine Report. 2017. Washington, DC: PMC; 2017. [cited 2018 Jan 25]. Available from: http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/The-Personalized-Medicine-Report1.pdf.

36. Yoon H.S., Kim S.H., Kim J.K., et al. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia. Ann Pharmacother. 2011;45(7-8):841-9. doi:10.1345/aph.1P511.

37. Belyalov F. Prognosis and scores in cardiology. Irkutsk: RIOIGMAPO; 2017. (In Russ.) [Белялов Ф.И. Прогнозирование и шкалы в кардиологии. Иркутск: РИО ИГМАПО; 2017].

38. Laiteerapong N., Cooper J.M., Skandari M.R., et al. Individualized Glycemic Control for U.S. Adults with Type 2 Diabetes: A Cost-Effectiveness Analysis. Ann Intern Med. 2018;168:170-8. doi:10.7326/M17-0537.

39. Fors A., Swedberg K., Ulin K., et al. Effects of person-centred care after an event of acute coronary syndrome: Two-year follow-up of a randomised controlled trial. Int J Card. 2017;249(Suppl C):42- 7. doi:10.1016/j.ijcard.2017.08.069.

40. Mills K.T., Obst K.M., Shen W., et al. Comparative effectiveness of implementation strategies for blood pressure control in hypertensive patients: A systematic review and meta-analysis. Ann Intern Med. 2018;168(2):110-20. doi:10.7326/M17-1805.


For citation:


Belyalov F.I. APPROACHES TO PERSONALIZED THERAPY. Rational Pharmacotherapy in Cardiology. 2018;14(3):418-424. (In Russ.) https://doi.org/10.20996/1819-6446-2018-14-3-418-424

Views: 108


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)